🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Postoperative Radiotherapy Followed by Immunotherapy for Locally Advanced Esophageal Carcinoma

RecruitingPhase 1, Phase 2Ages 18 Years - 75 YearsAllAnhui Provincial Hospital
NCT05937438 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Esophageal squamous cell carcinoma is a common malignancy in China. Although neoadjuvant chemoradiotherapy followed by esophagectomy remains a standard modality for locally advanced esophageal squamous cell carcinoma, esophagectomy followed by postoperative radiotherapy is also prevalent in China. Several retrospective studies demonstrated that postoperative radiotherapy could improve the prognosis of patients. Nevertheless, there still existed approximately 11.5% and 17.2% of total patients developing local-regional relapse and hematological metastasis. The result of Checkmate 577 has shown that postoperative immunotherapy of nivolumab could improve the disease-free survival (median Disease-free Survival 29.7 mos vs. 11.0 mos). Therefore, investigators aimed to implement a pilot study to explore the safety and efficacy of combining postoperative radiotherapy and immunotherapy for patien

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * 18-75 years old. * After esophagectomy. * Confirmation of squamous cell carcinoma by pathological examination. * Pathological staging of pIIb-IVa. * Over 12 lymph nodes dissected during surgery. * ECOG 0-1. * Signature of inform consent by patients Exclusion Criteria: * Younger than 18 years old or older than 75 years old. * Without esophagectomy. * Non-squamous cell carcinoma. * Pathological staging of pI, IIa, IVb. * Less than 12 lymph nodes dissected during surgery. * ECOG 2-3 g. no signature of inform consent.
💊

What it tests

  • Immune Checkpoint Inhibitors
📍

Where

1 site
Anhui Provicial Hospital
Hefei, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy